BLBryan L. Love

Bryan L. Love

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bryan L. Love has a total of 186 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Eluxadoline Utilization in Medicare Part D, 2016–23: National Trends, Geographic Variation, Prescriber-Type Patterns, and Spending

    by Avery R. Hammersmith, Ismaeel Yunusa, Chao Cai, Bryan L. Love

    Background Eluxadoline is a US Food and Drug Administration-approved therapy for irritable bowel syndrome with diarrhea and has important contraindications that may influence uptake in older adults. Medicare Part D dispensing patterns remain poorly characterized. Objective This study aimed to characterize national and state-level trends in eluxadoline dispensing and spending in Medicare Part D from 2016–2023, including geographic variation in population-adjusted rates and differences in dispensing intensity by prescriber type. Methods We conducted a retrospective repeated cross-sectional analysis using Centers for Medicare & Medicaid Services Medicare Part D Prescribers-by Provider and Drug Public Use Files from 2016 to 2023. Utilization was summarized using standardized 30-day fills (primary) and claims (secondary); state intensity was measured as fills per 100,000 Part D utilizers. Geographic concentration and outliers in state rates were assessed using Gini coefficients and median absolute deviation-based outlier detection. Prescriber-type differences in dispensing intensity were evaluated with negative binomial models of claims with National Provider Identifier-clustered standard errors. Results The Public Use Files contained 7826 prescriber-year observations from 3866 prescribers. National 30-day fills rose from 4410.9 (2016) to 19,860.2 (2018) and declined to 15,326.0 (2023). Median state rates increased from 7.3 per 100,000 (2016) to 43.7 (2018) and were 27.6–35.9 in 2019–23; California, Texas, New Jersey, New York, and Florida accounted for 39.5% of fills. State utilizer counts correlated with total fills (ρ 0.80–0.89) more than adjusted rates (ρ 0.03–0.34). Geographic concentration remained moderate in 2018–23 (Gini 0.307–0.352), and New Jersey was a recurrent high-rate outlier. Gastroenterologists comprised 41.5–57.4% of prescribers and had higher claim intensity than primary care (incidence rate ratio 1.17, 95% confidence interval 1.13–1.21). Inflation-adjusted cost per standardized fill increased from $1021 to $1414. Conclusions Eluxadoline dispensing in Medicare Part D is geographically concentrated and heterogeneous, with higher intensity among gastroenterologists. These descriptive benchmarks may inform medication-use monitoring, access and coverage evaluation, and future beneficiary-level studies of safety and appropriateness in irritable bowel syndrome with diarrhea care.

  • Open Access

    Risk of bradycardia and syncope associated with the use of cholinesterase inhibitors in patients with Alzheimer disease and related dementias: A systematic review and meta-analysis

    by Chijioke M. Okeke, Tenia Slade, Sarah Beth Tucker, Olivia Whitworth, Amey Rane, Bryan L. Love, Ibraheem M. Karaye, Saud Alsahali, Nasim Maleki, Nawaf M. Alotaibi, et al.

  • Impact of Intravenous Hydrocortisone on Postoperative Atrial Fibrillation and Outcomes in Patients Receiving Vasopressor Support Following On-Pump Coronary Artery Bypass Grafting

    by Emma Paytes, Breanne Mefford, Bryan Love, Arran Amick, Jenna Cox

    Background: Although 2019 EACTS Guidelines on Cardiopulmonary Bypass in Adult Cardiac Surgery recommend against routine use of prophylactic corticosteroids, perioperative glucocorticoids are still often used to mitigate hypotension, cardiac arrhythmias and respiratory failure following surgery with cardiopulmonary bypass (CPB). Limited data exists on safety and efficacy of intravenous (IV) hydrocortisone in this setting. Objectives: To assess the impact of intravenous hydrocortisone on postoperative complications after on-pump coronary artery bypass grafting (CABG). Methods: This was a single-center, retrospective chart review between 2021 and 2023. Adult patients with on-pump CABG requiring vasopressor therapy postoperatively were included. Results: Of 153 patients included, 39 received IV hydrocortisone and 114 did not. The hydrocortisone group had significantly lower cortisol levels (15.8 mcg/dL vs 23.9 mcg/dL, P < 0.001) and higher incidence of a past medical history of atrial fibrillation (23.1% vs 2.6%, P < 0.001) compared to the control group. Rates of postoperative atrial fibrillation (POAF) were similar between groups with 23.1% in the hydrocortisone group and 21.9% in the control group ( P = 0.88), which maintained after controlling for age, history of atrial fibrillation, sex, and propensity score ( P = 0.86). Mean cumulative norepinephrine equivalents (NEE) were similar between hydrocortisone group and control (10.4 mcg/min vs 8.9 mcg/min, P = 0.12). Hydrocortisone administration was associated with longer durations of vasopressor therapy (45.8 vs 28.9 hours, P = 0.001), insulin therapy (149.4 vs 82.2 hours, P = 0.003), and total mechanical ventilation time (59.3 vs 19.4 hours, P = 0.049). There were no differences in surgical site infections between the hydrocortisone group versus control group (5.2% vs 5.2%, P = 1.00), including both non-infectious (2.6% vs 2.6%, P = 1.00) and infectious surgical site complications (2.6% vs 2.6%, P = 1.00). Conclusion: After controlling for sex, age, history of atrial fibrillation/flutter, and propensity score, there was no significant association between the administration of IV hydrocortisone and POAF in patients receiving vasopressor support following on-pump CABG. Further prospective studies are needed to confirm these findings.


  • Open Access

    A Case Report of Ruptured Popliteal Aneurysm in the Setting of Blunt Trauma

    by Jaymes A.J. Lonzanida, Bryan E. Love, Brian L. Anderson

    Introduction: Popliteal artery aneurysms are in most cases asymptomatic but cause significant complications if ruptured. An acute popliteal aneurysm rupture is relatively rare, and few cases have been documented secondary to blunt trauma. Common presenting signs and symptoms include distal limb ischemia and absent dorsalis pedis pulses. Timely management and recognition of this rare presentation are crucial as this condition can result in limb loss or death if not treated in a timely manner.Case Report: An 80-year-old man with history of hypertension presented to the emergency department complaining of inability to feel sensation below his left knee after falling from ground level. Physical examination was pertinent for bounding radial and femoral pulses bilaterally, although absent dorsalis pedis and posterior tibial pulses to the left lower extremity. Computed tomography angiography identified occlusion of the left superficial femoral arterial lumen associated with a ruptured popliteal aneurysm, approximately eight centimeters in size. He immediately received unfractionated heparin and was admitted to the hospital for left medial thigh exploration and decompressive dermatofasciotomy.Conclusion: After confirmation of popliteal aneurysmal rupture with advanced imaging, heparinization and vascular surgery consultation are critical steps that should be taken to prevent limb loss.


  • Open Access

    Associations Between Opioid Prescriptions and Use of Hospital-Based Services Among US Adults with Longstanding Physical Disability or Inflammatory Conditions Compared to Other Adults in the Medical Panel 2010-2015

    by Margaret A Turk, Suzanne McDermott, Wanfang Zhang, Bo Cai, Bryan L Love, NaTasha Hollis

    Purpose: To investigate the association of filling opioid prescriptions with healthcare service utilization among a nationally representative sample of adults with disability.Materials and Methods: The Medical Expenditure Panel Survey (MEPS) for 2010-2015, Panels 15-19, was used to identify adults who were prescribed opioids during each two-year period. We examined the data for associations between opioid prescription filling and the number of emergency department (ED) visits and hospitalizations. The participants were grouped as those with inflammatory conditions or with longstanding physical disability, and a comparison group of those without these conditions.Results and conclusions: Opioid prescription filling differed among adults with inflammatory conditions and longstanding physical disability compared to the comparison group (44.93% and 40.70% vs 18.10%, respectively). For both groups of people with disability, the relative rates for an ED visit or hospitalization were significantly higher for those who filled an opioid prescription, compared to adults with the same conditions who did not fill an opioid prescription. People with a longstanding physical disability who filled an opioid prescription had the highest rate ratio of ED use and hospitalization. Results from this investigation demonstrate that opioid prescription filling among persons with inflammatory conditions and longstanding physical disabilities is associated with higher rates of ED visits and hospitalizations.


  • The impact of statin use prior to intensive care unit admission on critically ill patients with sepsis

    by Eric E. Chinaeke, Bryan L. Love, Joe Magagnoli, Ismaeel Yunusa, Gene Reeder

    Objective: To evaluate the impact of pre‐intensive care unit admission (pre‐ICU) statin use on all‐cause in‐hospital mortality and ICU length of stay (LOS).Design: Retrospective cohort study.Setting: Adult ICUs at tertiary hospitals.Patients: Adult critically ill patients diagnosed with sepsis admitted to the ICUs.Intervention: The exposure was pre‐ICU statin prescription (statin users); unexposed represented absence of pre‐ICU prescription (non‐users).Measurement and Main Results: We used the 2001–2012 Medical Information Mart for Intensive Care‐III (MIMIC‐III) database to determine average treatment effect (ATE) of pre‐ICU statin use on 30‐day ICU mortality, ICU LOS, and 30‐day in‐hospital mortality using the Augmented Inverse Propensity Weighted technique (AIPW), after adjusting for confounding factors (age, race, health insurance, corticosteroids use, vital signs, laboratory tests, and Sequential Organ Failure Assessment score (SOFA). We measured 30‐day ICU mortality as deaths within 30 days of admission to the ICU, and ICU LOS was measured in fractional days. A 30‐day in‐hospital mortality was measured as death within 30 days of hospital admission. A total of 8200 patients with sepsis were identified; 19.8% (1623) were statin users, and 80.2% (6577) were non‐users. Most were Caucasian, aged 80 years and above, and male. After adjusting for confounding factors, pre‐ICU statin use decreased 30‐day ICU mortality (ATE, −0.026; 95% confidence interval [CI], −0.048 to −0.009); ICU LOS (ATE, −0.369; 95% Cl, −0.849 to −0.096); and 30‐day in‐hospital mortality (ATE, −0.039; 95% CI, −0.084 to −0.026) on average compared with non‐statin use, respectively. In a stratified analysis, the result for ICU LOS (ATE, −0.526; 95% CI, −0.879 to −0.241) and 30‐day in‐hospital mortality (ATE, −0.023; 95% CI, −0.048 to −0.002) was consistent among patients admitted to the medical ICU.Conclusions: Among patients with sepsis admitted to the medical ICU, pre‐ICU statin use is causally associated with a decrease in 30‐day ICU mortality, ICU LOS, and 30‐day in‐hospital mortality compared to non‐use. This study adds to the totality of evidence on the pleiotropic effect of statin use in patients with sepsis.


  • Open Access

    Effectiveness of Conjugate and Polysaccharide Pneumococcal Vaccines for Prevention of Severe Pneumococcal Disease Among Inflammatory Bowel Disease Patients

    by Bryan L Love, Christopher J Finney, Jill K J Gaidos

    Background: Streptococcus pneumoniae is an important pathogen responsible for severe pneumococcal diseases, including pneumonia, bacteraemia/sepsis, and meningitis. Inflammatory bowel disease [IBD] patients have an increased risk for infections due to an altered immune system and treatment with immunosuppressive medications. The aim of this study was to assess the prevalence of severe pneumococcal disease [SPD] and evaluate the impact of pneumococcal vaccination on the risk of SPD in Veterans with IBD. Methods: Subjects with IBD and SPD were identified from the VA Health Administration database using ICD9/10 codes. Pneumococcal vaccination and use of immunosuppressant medications were collected. Risk of SPD was evaluated using an adjusted Cox proportional hazards model controlling for demographics, medications, vaccination, and comorbidities. Results: A total of 1798 cases of SPD were identified [283 pneumonia, 1513 bacteraemia, and two meningitis]. SPD patients were older [60.9 years vs 59.4 years; p <0.001], had more comorbidities [Charlson Comorbidity Index of 2.11 vs 0.96; p <0.001], and had increased mortality [4.6% vs 1.5%, p <0.001]. The risk of SPD was increased in Crohn’s disease (hazard ratio [HR] 1.15; 95% confidence interval [CI] 1.05–1.27) and with more comorbidities [HR 1.45; 95% CI 1.42–1.48]. Use of immunosuppressive medications increased the risk of SPD. Receipt of PCV13 either alone or in combination with PPSV23 predicted a 5-fold decreased risk of SPD compared with no vaccination. Conclusions: Risk factors for severe pneumococcal disease include having Crohn’s disease, more comorbidities, and exposure to combination immunosuppression. Vaccination with PCV13 alone or in combination with PPSV23 and revaccination with PPSV23, was protective against SPD. All IBD patients should be evaluated for pneumococcal vaccination, particularly those receiving or expected to receive immunosuppressive therapies.


  • Open Access

    Changes in Cost-Effectiveness for Chronic Hepatitis C Virus Pharmacotherapy: The Case for Continuous Cost-Effectiveness Analyses

    by T. Joseph Mattingly, Bryan L. Love

    BACKGROUND: Cost-effectiveness evaluations for hepatitis C virus (HCV) treatments have been published frequently, but new products with significant cost and effectiveness differences make these ana...


  • Open Access

    Publisher Correction: Early-onset colorectal cancer: initial clues and current views

    by Lorne J. Hofseth, James R. Hebert, Anindya Chanda, Hexin Chen, Bryan L. Love, Maria M. Pena, E. Angela Murphy, Mathew Sajish, Amit Sheth, Phillip J. Buckhaults, et al.

    An amendment to this paper has been published and can be accessed via a link at the top of the paper.